Skip to main content

Advertisement

SpringerLink
Log in

Botulinum toxin treatment for overactive bladder and detrusor overactivity in adults

  • Topic paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Objectives

To review the evidence in support of botulinum toxin (BoNT-A) for overactive bladder and detrusor overactivity in adults.

Methods

A search of Medline and Pubmed was undertaken using the search terms ‘botulinum toxin’ with ‘overactive bladder’, ‘detrusor overactivity’, ‘randomised trial’ and ‘trial’. A narrative review was undertaken based on the papers identified.

Results

Only four randomised trials reporting the effects of botulinum toxin in this group of patients exist, alongside three systematic reviews and numerous uncontrolled series. Overall, BoNT-A appears an effective treatment modality, with significant and clinically meaningful reductions in urinary symptoms. Urgency and urgency incontinence episodes appear more responsive than absolute frequency. The side effect profile can be predicted from the mode of action of BoNT-A and includes voiding difficulty and urinary tract infection. Few data exist comparing the efficacy and safety of different doses, nor directly comparing the two common preparations, onabotulintum toxin A with apobotulinum toxin A. The cost-effectiveness of BoNT-A remains to be fully evaluated.

Conclusions

BoNT-A is an emerging treatment for overactive bladder and detrusor overactivity. The data available to date are of moderate quality with few large randomised trials. However, the drug appears to be effective and safe, although further work is required to identify the most cost-effective dose and treatment interval for maximum benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Turner DA, Shaw C, McGrother CW et al (2004) The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK. BJU Int 93:1246–1252

    Article  PubMed  CAS  Google Scholar 

  2. Irwin DE, Mungapen L, Milsom I et al (2009) The economic impact of overactive bladder syndrome in six Western countries. BJU Int 103:202–209

    Article  PubMed  Google Scholar 

  3. Onukwugha E, Zuckerman IH, McNally D et al (2009) The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care 15:S90–S97

    PubMed  Google Scholar 

  4. Kannan H, Radican L, Turpin RS et al (2009) Burden of illness associated with lower urinary tract symptoms including overactive bladder/urinary incontinence. Urology 74:34–38

    Article  PubMed  Google Scholar 

  5. Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178

    Article  PubMed  Google Scholar 

  6. Burgio KL, Locher JL, Goode PS et al (1998) Behavioral versus drug treatment for urge urinary incontinence in older women. JAMA 280:1995–2000

    Article  PubMed  CAS  Google Scholar 

  7. Kirkali Z, Whitaker RH (1987) The use of oxybutynin in urological practice. Int Urol Nephrol 19:385–391

    Article  PubMed  CAS  Google Scholar 

  8. Abrams P, Freeman RM, Anderstrom C et al (1999) Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81:801–810

    Google Scholar 

  9. Chapple CR, Rechberger T, Al-Shukri S et al (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93:303–310

    Article  PubMed  CAS  Google Scholar 

  10. Herbison P, Hay-Smith J, Ellis G et al (2003) Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 326:841–844

    Article  PubMed  CAS  Google Scholar 

  11. Kelleher CJ, Cardozo LD, Khullar V et al (1997) A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104:988–993

    Article  PubMed  CAS  Google Scholar 

  12. Jankovic J, Brin MF (1991) Therapeutic uses of botulinum toxin. New Eng J Med 324:1186–1194

    Article  PubMed  CAS  Google Scholar 

  13. Dolly O (2003) Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 43(1):S16–S24

    Article  PubMed  Google Scholar 

  14. Apostolidis A, Dasgupta P, Fowler CJ (2006) Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49:644–650

    Article  PubMed  CAS  Google Scholar 

  15. Mangera A, Andersson KE, Apostolidis A et al (2011) Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA). Eur Urol doi:10.1016/j.eururo.2011.07.001

  16. Grosse J, Kramer G, Jakse G (2009) Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study. BJU Int 104:651–656

    Article  PubMed  CAS  Google Scholar 

  17. Schurch B, Stöhrer M, Kramer G et al (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697

    Article  PubMed  CAS  Google Scholar 

  18. Schurch B, de Seze M, Denys P et al (2005) Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174:196–200

    Article  PubMed  CAS  Google Scholar 

  19. Reitz A, Stöhrer M, Kramer G et al (2004) European Experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510–515

    Article  PubMed  CAS  Google Scholar 

  20. Grosse J, Kramer G, Stohrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:653–659

    Article  PubMed  CAS  Google Scholar 

  21. Popat R, Aspostolidis A, Kalsi V et al (2005) A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174:984–989

    Article  PubMed  CAS  Google Scholar 

  22. Rapp DE, Lucioni A, Katz EE et al (2004) Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 63:1071–1075

    Article  PubMed  Google Scholar 

  23. Schulte-Baukloh H, Weiss C, Stolze T et al (2005) Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patients satisfaction. Urology 66:82–87

    Article  PubMed  Google Scholar 

  24. Dmochowski R, Chapple C, Nitti VW et al (2010) Efficacy and safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial. J Urol 184:2416–2422

    Article  PubMed  CAS  Google Scholar 

  25. Sahai A, Khan MS, Dasgupta P (2007) Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 177:2231–2236

    Article  PubMed  CAS  Google Scholar 

  26. Flynn MK, Amundsen CL, Perevich M et al (2009) Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 181:2608–2615

    Article  PubMed  CAS  Google Scholar 

  27. Brubaker L, Richter HE, Visco A et al (2008) Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 180:217–222

    Article  PubMed  Google Scholar 

  28. Yalcin I, Bump RC (2003) Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 189:98–101

    Article  PubMed  Google Scholar 

  29. Tincello DG, Slack MC, Kenyon S et al (2011) Botulinum toxin-A for refractory detrusor overactivity in women: a 240 patient randomised placebo controlled trial. Eur Urol 10(2):191

    Google Scholar 

  30. Chapple C, Van KP, Tubaro A et al (2007) Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 52:1204–1212

    Article  PubMed  CAS  Google Scholar 

  31. Chapple CR, Martinez-Garcia R, Selvaggi L et al (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48:464–470

    Article  PubMed  CAS  Google Scholar 

  32. Wyndaele JJ, van Dromme SA (2002) Muscular weakness as side effect of botulinum toxin injection of neurogenic detrusor overactivity. Spinal Cord 40:599–600

    Article  PubMed  CAS  Google Scholar 

  33. De Laet K, Wyndaele JJ (2005) Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord 43:397–399

    Article  PubMed  Google Scholar 

  34. Bauer RM, Gratzke C, Roosen A et al (2011) Patient-reported side effects of intradetrusor botulinum toxin type a for idiopathic overactive bladder syndrome. Urol Int 86:68–72

    Article  PubMed  CAS  Google Scholar 

  35. Duthie JB, Herbison GP, Wilson DI et al (2009) Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev (3):CD00549. doi:10.1002/14651858.CD005493.pub2

  36. Anger JT, Weinberg A, Suttorp MJ et al (2010) Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J Urol 183:228–2264

    Article  Google Scholar 

  37. Apostolidis A, Dasgupta P, Denys P et al (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European Consensus Report. Eur Urol 55:100–120

    Article  PubMed  CAS  Google Scholar 

  38. Cohen BL, Barboglio P, Rodriguez D et al (2009) Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 28:205–208

    Article  PubMed  CAS  Google Scholar 

  39. Coelho AC, Cruz F, Cruz CD et al (2011) Spread of Onabotulinum A after injection in the bladder wall. Experimental study in guinea-pig urinary bladder using the distribution of cleaved SNAP-25. Eur Urol 10(2):189

    Google Scholar 

  40. Cohen BL, Caruso DJ, Kanagarajah P et al (2009) Predictors of response to intradetrusor botulinum toxin-A injections in patients with idiopathic overactive bladder. Adv Urol doi:10.1155/2009/328364

  41. Kalsi V, Popat RB, Apostolidis A et al (2006) Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 49:519–527

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

Dr Tincello is principal investigator on a multicentre randomised trial with open label follow-up of onabotulinum toxin A for idiopathic DO. Study drugs were provided free of charge by Allergan, but no other financial or consultancy arrangements exist. Dr Tincello has received honoraria payments for advisory board work for Pfizer and Ethicon, managed by the University of Leicester Research Office.

Author information

Authors and Affiliations

  1. Reproductive Science Section, Cancer Studies and Molecular Medicine, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, PO Box 65, Leicester, LE2 7LX, UK

    Douglas G. Tincello

Authors
  1. Douglas G. Tincello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas G. Tincello.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tincello, D.G. Botulinum toxin treatment for overactive bladder and detrusor overactivity in adults. World J Urol 30, 451–456 (2012). https://doi.org/10.1007/s00345-011-0778-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-011-0778-9

Keywords

Search

Navigation